Delhi, India (PressExposure) June 10, 2008 -- RNCOS has recently added a new Market Research Report titled, "Emerging Pharmaceutical Markets Globally" to its report gallery. This Report provides a detailed account of the factors that are redefining the structure and composition of the global pharmaceutical market and causing a shift in growth from the mature markets to the emerging ones.
Statistics and analysis regarding market size, growth, structure, exports and imports, therapy mix, share of branded and generic drugs, healthcare financing, market share of key players, as well as key drivers and restraints and trends in technology development have been thoroughly analyzed in this report.
The report also envisages the fact that the markets in the E7 have huge differences as compared to the developed markets in terms of traditional therapies, intellectual property, health insurance scenario and so forth. Thus, it provides valuable information to pharmaceutical companies and investors looking to foray into these markets and help them devise strategies according to the E7 markets.
- The E7 Pharmaceutical markets are expected to grow at a CAGR 11.5% between 2007 and 2012 reaching revenues worth nearly US$ 116 Billion. In contrast the G7 Pharmaceutical markets are projected to grow at CAGR 4.95% between the same periods. - The pharmaceutical markets in India, China and Turkey are expected to grow the fastest among all the E7 nations. - The E7 nations are expected to account for nearly half of the 6.99 Billion global populations in 2012. - Cardiovascular, cancer and other chronic diseases have taken over communicable diseases as the biggest killers in these nations. - The Pharmaceutical market in most of these regions is still dominated by acute therapies, but with the growth rate of chronic therapies far exceeding that of acute therapies, the therapy mix of the market will be much different in the next five years from what it is today. - The markets in India, China, Russia and Indonesia are dominated by generics. Generics however have a lower penetration in Brazil, Mexico and Turkey. - Inadequate protection of intellectual property and large-scale prevalence of counterfeit drugs remains a major challenge faced by the pharmaceutical industry in these regions.
Key Issues & Facts Analyzed
- Evaluation of past, current and future market trends. - Evaluation of the market by segment. - Discussion about the major drivers of the pharmaceutical market. - Analysis of the opportunities created by the market. - Analysis of the major challenges faced by the market. - Competitive landscape of the market.
Key Players Analyzed
This section provides the overview, key facts and financial information of prominent players in the E7 pharmaceutical market like GlaxoSmithKline, Sanofi-Aventis, Pfizer Inc., Novartis, and AstraZeneca.
Research Methodology Used
Information Sources Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
Analysis Methods The analysis methods include ratio analysis, historical trend analysis, and linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.
For more information visit: [http://rncos.com/Report/IM081.htm] Current Industry News: [http://www.rncos.com/Blog/]